OMRIX biopharmaceuticals LTD

Omrix Biopharmaceuticals LTD is a biotechnology company belonging to the Johnson & Johnson group, founded in 1995.
Omrix leads innovation and specializes in the development and production of life-saving medical preparations derived from human plasma. As part of the company's Credo ("I believe") values , Omrix is committed to changing and improving the quality of patients' lives and sees the development of its products as a mission and responsibility towards the patient population, their families and the medical teams.

Omrix specializes in products based on human plasma:
the first product line deals with biological adhesives for the world of biosurgery and includes several innovative developments that are considered world news in stopping massive internal bleeding.
The first development in this line, the Evicel® , won in 2012 the most prestigious research and development award of Johnson & Johnson. The second development, the EVARREST® , was launched in 2015, and became the most innovative flagship product in the field of stopping bleeding and amazed the medical community in the USA. The EVARREST® even earned Omrix the Global Surgery.